osteosarcoma
Umoja Biopharma Raises $210M in Series B Funding Round
The funding will help the company advance two CAR T-cell therapies into clinical development for solid tumors and blood cancers.
Study Finds 28 Percent of Osteosarcoma Patients Have High-Penetrance Germline Mutations
The authors of the study noted that these genetic findings could guide better clinical decisions for patients and improve outcomes.
Profiling of Osteosarcomas Uncovers Numerous Mechanisms Blocking Immune Checkpoint Inhibitor Therapy Response
The analysis also suggested ways to outwit these mechanisms based on the degree of immune cell infiltration into the tumor.
NCI Pediatric MATCH Trial Interim Data Shows 24 Percent of Patients Eligible for Targeted Therapy
Premium
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.